In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
386 News Items found
MSK scientists Charles Rudin and John Poirier
In the Lab
Scientists Home in on Treatment Advance for Chemotherapy-Resistant Small Cell Lung Cancer

An epigenetic mechanism may make small cell lung cancer vulnerable to a new kind of attack.
scientific image
In the Clinic
Personalized Medicine 2.0: MSK Leads the Way in the Study of Drug Resistance in Lung Cancer

Overcoming resistance to drug treatment for lung cancer is a critical challenge.
Charles Rudin and David Jones, leaders of the Druckenmiller Center
In the Clinic
MSK’s New Fiona and Stanley Druckenmiller Center for Lung Cancer Research Takes on Biggest Cancer Killer

The new Fiona and Stanley Druckenmiller Center for Lung Cancer Research brings together MSK physicians and scientists in an intensive, multidisciplinary effort against the number-one cause of death from cancer in the nation.
Memorial Sloan Kettering neuro-oncologist Adrienne Boire
Roundup
Year in Review: Five Important Clinical Advances in Cancer in 2020

Read about some of the most important clinical advances made at MSK in 2020.
Charles Rudin and Dana Pe'er
Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why It’s So Aggressive

Stem-like cells that make up only a tiny fraction of the total cells in a lung tumor could be the key to stopping the disease’s deadly spread, say researchers at Memorial Sloan Kettering.
Physician-scientist Piro Lito
In the Lab
Why KRAS Inhibitors for Lung Cancer Stop Working (and What Can Be Done about It)

Recently developed targeted drugs used to treat lung cancer are only partially effective. Scientists now know why.
MSK Scientists Reveal Biology of Shape-Shifting Lung Cancer

Lung cancer has an uncanny ability to change its identity to resist drugs. Researchers are learning what drives these changes.
Alexander Drilon, MD
Targeted Therapy Selpercatinib Approved for Lung and Thyroid Cancers With RET Gene Mutations or Fusions

The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to selpercatinib (Retevmo™) for lung and thyroid cancers with RET (REarranged during Transfection) gene mutations or fusions.
Cartoon of different-color heads with speaker and thought bubbles above them.
Feature
What You Should Know about Five Common Cancers

Even the most common cancers have aspects that are not fully grasped by the public.
scientific image of mouse lung cancer cells
Lung Cancer Cells’ ‘Memories’ Suggest New Strategy For Improving Treatment

Research from the lab of cancer biologist Tuomas Tammela shows that some lung cancer cells retain a “memory” of the healthy cell where they came from — one that might be exploited to make an emerging type of lung cancer treatment called KRAS inhibition more effective.